GW and Otsuka pursue US MS indication for cannabis-derived Sativex
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals and its US partner Otsuka Pharmaceuticals are finally planning on targeting multiple sclerosis (MS) in the US market with their cannabis-derived medicine Sativex.